You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Key Advances in the Treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

  • Authors: Oliver Distler, MD; Jacob van Laar, MD, PhD; Vanessa Smith, MD, PhD; Anna-Maria Hoffmann-Vold, MD, PhD; Yannick Allanore, MD, PhD
  • CPD Released: 8/29/2018
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/29/2019, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US rheumatologists, pulmonologists, allergists, and clinical immunologists.

The treatment landscape for patients with SSc-ILD is evolving. Physicians have a critical need to understand the pathogenesis of SSc-ILD, the rationale and mode of action for the development of new treatments, and the efficacy and safety profiles of current and emerging therapies.

Upon completion of this activity, participants will have increased knowledge regarding the:

  • Complexity of SSc-ILD and evolving treatment landscape
  • Key data on current and emerging treatments for SSc-ILD
  • Expert opinions on the implications for clinical practice


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Moderator

  • Oliver Distler, MD

    Professor
    Department of Rheumatology
    University Hospital Zurich
    Zurich, Switzerland

    Disclosures

    Disclosure: Oliver Distler, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; AnaMar; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; CSL Behring; GlaxoSmithKline; Inventiva; Italfarmaco; Medac; Merck & Co., Inc.; Mitsubishi Tanabe Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Target BioScience AG; UCB Pharma, Inc.
    Received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Mitsubishi Tanabe Parma; Roche Holdings AG

Faculty

  • Yannick Allanore, MD, PhD

    Professor
    Paris Descartes University
    Cochin Hospital
    Paris, France

    Disclosures

    Disclosure: Yannick Allanore, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Inventiva; Medac; Roche Holdings AG
    Received grants for clinical research from: Roche Holdings AG; Inventiva

  • Anna -Maria Hoffmann-Vold, MD, PhD

    Doctor
    Oslo University Hospital
    Oslo, Norway

    Disclosures

    Disclosure: Anna-Maria Hoffmann-Vold, MD, PhD, has disclosed no relevant financial relationships.

  • Vanessa Smith, MD, PhD

    Professor
    Ghent University
    Ghent University Hospital
    Ghent, Oost Vlaanderen, Belgium

    Disclosures

    Disclosure: Vanessa Smith, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.
    Served as a speaker or a member of a speakers bureau for: Accord Healthcare; Actelion Pharmaceuticals, Ltd
    Received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Belgium Fund for Scientific Research in Rheumatic diseases; Fund of Scientific Research Flanders; Galapagos NV; Roche Holdings AG

  • Jacob van Laar, MD, PhD

    Professor
    Department of Rheumatology and Clinical Immunology
    University Medical Center Utrecht
    Utrecht, the Netherlands

    Disclosures

    Disclosure: Jacob van Laar, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Eli Lilly and Company; Merck Sharp & Dohme Corp.; Roche
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Merck Sharp & Dohme Corp.; Roche

Steering Committee

  • Luca Richeldi, MD, PhD (Chair)

    Professor
    Catholic University of the Sacred Heart
    Agostino Gemelli University Hospital
    Rome, Italy

    Disclosures

    Disclosure: Luca Richeldi, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; InterMune, Inc.; Roche
    Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Cipla Ltd.; Roche; Vertex Pharmaceuticals Incorporated
    Received grants for clinical research from: InterMune, Inc.

Members

  • Kevin Brown, MD

    Professor
    Vice Chair
    National Jewish Health
    Denver, Colorado, United States

    Disclosures

    Disclosure: Kevin Brown, MD, has disclosed the following relevant financial relationships:
    Other: Aeolus Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; aTyr Pharma, Inc.; Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; FibroGen, Inc.; Galapagos NV; Galecto Biotech; Genentech, Inc.; Gilead Sciences, Inc.; MedImmune Inc.; Novartis Pharmaceuticals Corporation; Patara Pharma, LLC; ProMetic Pharma Inc.; Roche; Third Pole Therapeutics

  • Vincent Cottin, MD, PhD

    Professor
    University of Lyon
    Hôpital Louis Pradel
    Lyon, France

    Disclosures

    Disclosure: Vincent Cottin, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Galapagos NV; Gilead Sciences, Inc.; Promedior; Roche
    Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Roche
    Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Roche

  • Christopher P. Denton, PhD, FRCP

    Professor
    Royal Free Hospital and University College London
    London, United Kingdom

    Disclosures

    Disclosure: Christopher P. Denton, PhD, FRCP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Corbus Pharmaceuticals Holdings, Inc.; Inventiva; Sanofi Aventis; Roche
    Received grants for clinical research from: CSL Behring; GlaxoSmithKline; Inventiva; Roche

  • Marco Matucci-Cerenic, MD, PhD

    Professor
    University of Florence
    Florence, Italy

    Disclosures

    Disclosure: Marco Matucci-Cerenic, MD, PhD, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Actelion Pharmaceuticals, Ltd; Bristol-Myers Squibb Company; Pfizer Inc.
    Received grants for clinical research from: Actelion Pharmaceuticals, Ltd

  • Madelon M.C. Vonk, MD, PhD

    Assistant Professor
    Radboud University Medical Centre
    Nijmegen, the Netherlands

    Disclosures

    Disclosure: Madelon M.C. Vonk, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.
    Received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Therabel Pharma NV

Editor

  • Marinella Calle, PhD, CMPP

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.

  • Walid Amara, MD

    Scientific Director, WebMD Global, LLC

    Disclosures

    Walid Amara,MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BIOTRONIK; SERVIER
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude;Servier

Content Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Key Advances in the Treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

Authors: Oliver Distler, MD; Jacob van Laar, MD, PhD; Vanessa Smith, MD, PhD; Anna-Maria Hoffmann-Vold, MD, PhD; Yannick Allanore, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 8/29/2018

Valid for credit through: 8/29/2019, 11:59 PM EST

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Section 1. Key Advances in the Treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)
Dr Distler introduces the program and presents the different segments
Oliver Distler, MD
Section 2. Pathogenesis of SSc-ILD and Rationale for New Treatment Options
Dr van Laar presents the mechanisms implicated in SSc-ILD pathogenesis and discusses current and investigational treatments
Jacob van Laar, MD, PhD
Section 3. Overview of SSc-ILD Burden and Unmet Needs
Dr Smith presents the unmet needs in SSc-ILD and prognostic factors of this pathology
Vanessa Smith, MD, PhD
Section 4. Identifying SSc-ILD Patients at Risk of Progression
Dr Hoffmann-Vold addresses SSc-ILD progression and the factors, particularly biomarkers, than can be used to identify a risk of progression
Anna-Maria Hoffmann-Vold, MD, PhD
Section 5. Established Treatment Options for SSc-ILD
Dr Allanore presents the key data for established treatment options of SSc-ILD
Yannick Allanore, MD, PhD
Section 6. Emerging and Investigational Treatments for SSc-ILD
Dr Distler presents the rationale and the key data for antifibrotic therapies in SSc-ILD
Oliver Distler, MD
 

Educational Impact Challenge

The treatment landscape for patients with SSc-ILD is evolving. Physicians have a critical need to understand the pathogenesis of SSc-ILD, the rationale and mode of action for the development of new treatments, and the efficacy and safety profiles of current and emerging therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print